Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess clemastine as a remyelinating agent in patients with relapsing forms of multiple sclerosis. The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with multiple sclerosis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. The study will also assess the robustness and stability of this clinical effect in patients taking clemastine for up to 3 months. Patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653

Multiple Sclerosis (MS) Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Primary Progressive +4 more

RECRUITING PHASE1/PHASE2

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670

Demyelinating Diseases Demyelination; Corpus Callosum Multiple Sclerosis Brain Lesion +2 more

NOT_YET_RECRUITING PHASE1/PHASE2

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311

Optic Neuritis

RECRUITING PHASE2

CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy

NCT05131828

Multiple Sclerosis

COMPLETED PHASE2

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

NCT05338450

Multiple Sclerosis Internuclear Ophthalmoplegia

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3 months Clemastine, 2 months Placebo

4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months

Group Type ACTIVE_COMPARATOR

Clemastine

Intervention Type DRUG

4mg tablet twice daily

Placebo

Intervention Type DRUG

Placebo tablet twice daily

3 months Placebo , 2 months Clemastine

Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.

Group Type ACTIVE_COMPARATOR

Clemastine

Intervention Type DRUG

4mg tablet twice daily

Placebo

Intervention Type DRUG

Placebo tablet twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clemastine

4mg tablet twice daily

Intervention Type DRUG

Placebo

Placebo tablet twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Clemastine Fumarate, Tavist -1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Relapsing remitting Multiple Sclerosis by 2010 Revised McDonald Criteria
* Age 18-60.
* Latency delay \> 125 milliseconds on baseline full-field transient pattern reversal visual evoked potential (VEP) in at least one eye (electrophysiological evidence of demyelination)
* Retinal nerve fiber layer (RNFL) \> 70 microns on Spectralis Domain Optical Coherence Topography (SD-OCT) in the same eye meeting criteria for latency delay (sufficient axons)
* No optic neuritis in prior 6 months
* Stable immunomodulatory therapy - no switch or planned switch in \> 6 months and no change in doses in 30 days prior to screening
* Use of appropriate contraception during period of trial (females of child bearing potential)
* Understand and sign informed consent.
* Expanded disability status scale (EDSS) 0-6.0 (inclusive)

Exclusion Criteria

* Major ophthalmologic disease / Concomitant ophthalmologic disorders (e.g. diabetes, macular degeneration, glaucoma, severe myopia , etc).
* Myopia \> -7 Diopters (Severe myopia)
* History of significant cardiac conduction block
* History of cancer
* Known optic neuritis in involved eye \> 5 years ago OR disease duration \> 15 years
* Suicidal ideation or behaviour in 6 months prior to screening
* Pregnancy, breastfeeding, or planning to become pregnant.
* Involved with other study protocol simultaneously without prior approval. 9. Concomitant use of Dalfampridine (4AP or diamino4AP) or any other formulation of 4AP or diamino4AP.
* Concomitant use of any other putative remyelinating therapy as determined by investigator.
* Treatment with corticosteroids within 30 days prior to screening
* Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination
* Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide
* Serum creatinine \> 1.5 mg/dL; aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase \> 2 times the upper limit of normal
* History of drug or alcohol abuse within the past year
* Untreated vitamin B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid (MMA) and homocysteine) or untreated hypothyroidism
* Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, psychiatric allergic, renal or other major diseases that in the PI's judgment may affect interpretation of study results or patient safety.
* History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No